

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

<https://marketpublishers.com/r/C189DEB1582EN.html>

Date: May 2013

Pages: 301

Price: US\$ 2,100.00 (Single User License)

ID: C189DEB1582EN

Abstracts

The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets:

Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA)

G-CSF & GM-CSF

Thrombopoietin & Thrombopoiesis Stimulating Agents

Interferon

Insulin

Coagulation Factors

Human Growth Hormone (hGH)

FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART)

Thrombolytics & Fibrinolytics

Enzyme Replacement Therapies

Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Australasia.

With more than US\$ 50 bln in sales, therapeutic proteins represent a major category of pharmaceutical products with established therapeutic value and high economic attractiveness. As more and more of the branded products are running out of patent protection and regulatory agencies are providing better guidance, development of biosimilar versions as well as of improved next generation versions are a highly attractive goal for pharmaceutical and biotechnology as well as technology focused companies.

This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low

prices. The information is provided in a tabular format and fully referenced.

Contents

1) ERYTHROPOIESIS STIMULATING AGENTS (ESA)

First generation epoetins in regulated markets
Second generation epoetins in regulated markets
Epoetin biosimilars in regulated markets
Darbepoetin biosimilars in regulated markets
Next generation biologic Erythropoiesis Stimulating Agents (ESA) in regulated markets
Next generation small molecule Erythropoiesis Stimulating Agents
First generation EPO in less regulated markets (Latin America; Africa; Asia; RoW)
Darbepoietin biosimilars in less regulated markets
Next generation biologic ESAs in less regulated markets

2) G-CSF AND GM-CSF

2012 Sales of Branded G-CSF Products in Regulated Markets
1st Generation Branded G-CSF Products in Regulated Markets
Biosimilar 1st Generation G-CSF Products in Regulated Markets
Next Generation Branded G-CSF Products in Regulated Markets
Biosimilar Next Generation G-CSF Products in Regulated Markets
1st Generation G-CSF Products in Non-Regulated Markets: India
1st Generation G-CSF Products in Non-Regulated Markets: China & Taiwan
1st Generation G-CSF Products in Non-Regulated Markets – Korea
1st Generation G-CSF Products in Non-Regulated Markets – Latin America
1st Generation G-CSF Products in Non-Regulated Markets: Other Territories
Next Generation G-CSF Products in Non-Regulated Markets
1st and Next Generation GM-CSF Products in Regulated Markets
1st and Next Generation GM-CSF Products in Non-Regulated Markets

3) THROMBOPOIESIS-STIMULATING AGENTS (TPO; IL-11)

Thrombopoietin receptor (TPO-R) activators
Interleukin-11 (IL-11) receptor activators
Small molecule TPO-R Agonists
Corporate TPO/IL-11 Receptor Agonist Product Portfolios and R&D Pipelines

4) INTERFERON

a) INTERFERON alpha

- ##Interferon alpha sales 2012 of branded products in regulated markets
- ##1st generation Interferon alpha-2a in regulated markets
- ##1st generation Interferon alpha-2a in non-regulated markets
- ##Next generation Interferon alpha-2a in regulated markets
- ##Next generation Interferon alpha-2a in non-regulated markets and biosimilars
- ##1st generation Interferon alpha-2b in regulated markets
- ##1st generation Interferon alpha-2b in non-regulated markets and biosimilars
- ##Next generation Interferon alpha-2b in regulated markets
- ##Next generation Interferon alpha-2b in non-regulated markets and biosimilars
- ##Other Interferon alpha sub-types
- ##Interferon alpha with not specified sub-type – 1/2
- ##Purified natural human interferon alpha

b) Consensus INTERFERONS**c) INTERFERON beta**

- ##Interferon beta sales 2012 of branded products in regulated markets
- ##1st generation Interferon beta-1a in regulated markets
- ##1st generation Interferon beta-1a in non-regulated markets and biosimilars
- ##1st generation Interferon beta-1b in regulated markets
- ##1st generation Interferon beta-1b in non-regulated markets and biosimilars
- ##1st generation Interferon beta with not disclosed sub-type
- ##Next generation Interferon beta in regulated markets
- ##Purified natural human interferon beta

d) INTERFERON gamma**e) Other INTERFERONS****5) INSULIN**

- 2012 Sales of branded recombinant human insulins in regulated markets
- 2012 Sales of branded short-acting recombinant human insulin analogs in regulated markets
- 2012 Sales of branded long-acting recombinant human insulin analogs in regulated markets
- Rhu insulin (2nd generation) in regulated markets
- Biosimilar rhu insulin (2nd generation) in regulated markets
- Rhu insulin analogs (3rd generation) in regulated markets
- Biosimilar rhu insulin analogs (3rd generation) in regulated markets
- Ultra-long acting rhu insulin formulations and insulin analogs (4th generation)
- Ultra-fast acting rhu insulin formulations and insulin analogs (4th generation)

Combinations of modern basal and prandial insulin & analogs (4th generation)
Combinations of insulin & GLP-1 agonist (4th generation)
Other combinations with insulin
Oral and Transbuccal Insulins (5th generation)
Inhaled and transdermal insulin
Novel approaches for insulin therapy
Rhu insulin (2nd generation) in non-regulated markets: India
Rhu insulin (2nd generation) in non-regulated markets: China
Rhu insulin (2nd generation) in non-regulated markets: Other Territories
Modern insulin analogs (3rd generation) in non-regulated markets

6) COAGULATION FACTORS

Sales of Recombinant Coagulation Factors for Hemophilia in 2012

Coagulation Factor VIII

Coagulation Factor IX

Coagulation Factor VII

Coagulation Factors for Willebrand Disease

Fibrinogen

Factors XI, X and XIII

Alternative Procoagulants & Adjuncts

Human Plasma-Derived Prothrombin Complex Concentrates

Gene Therapy of Hemophilia

Topical Human Plasma-Derived Fibrinogen and Thrombin Products

Topical Plasma-Derived Thrombin Products

Topical Recombinant Human Factor II (Prothrombin)

Alternative Topical Hemostats

7) HUMAN GROWTH HORMONE (HGH)

2012 Sales of Branded Somatropin Products in Regulated Markets

2012 Sales of Selected Somatropin Products in Non-Regulated Markets

1st Generation: Somatropin in Regulated Markets

1st Generation: Biosimilar Somatropin in Regulated Markets

2nd Generation: Injectable Somatropin in Slow-release Formulation in Regulated Markets

2nd Generation: Injectable Long-acting Somatropin in Regulated Markets

2nd Generation: Injection-Free Somatropin in Regulated Markets

1st Generation: Somatropin Products in Non-Regulated Markets

2nd Generation: Injectable Long-Acting Somatropin Products in Non-Regulated Markets

8) FSH, HCG AND LH - ASSISTED REPRODUCTIVE TECHNOLOGY (ART)

Urinary FSH-Containing Products: Menotropins

Recombinant Menotropins

1st Generation Purified Human Urinary FSH

2nd Generation Recombinant Human FSH

Biosimilar Recombinant Human FSH

2nd Generation Rhu FSH in Non-Regulated Markets

3rd Generation Rhu FSH

Purified Urinary Human Choriogonadotropin (hCG)

Recombinant Human Choriogonadotropin (rhCG)

Recombinant Human Luteinizing Hormone (rhLH)

hCG Receptor Agonist

9) THROMBOLYTICS & FIBRINOLYTICS

Non-fibrin selective (1st generation) Fibrinolytics

Fibrin selective wild-type t-PA-based Fibrinolytics

Fibrin selective engineered t-PA-based Fibrinolytics

Non-t-PA-based Fibrinolytics

Plasmin-based Fibrinolytics

Adjunctive therapy to Fibrinolytics

Biosimilar Thrombolytics and Fibrinolytics in Non-Regulated Markets

10) ENZYME REPLACEMENT THERAPIES

Gaucher Disease

Fabry Disease

Pompe Disease

Hunter Disease (MPS II)

Niemann Pick Diseases

Mucopolysaccharidosis I (MPS I)

San Filippo Syndrome (MPS IIIA)

Morquio Syndrome (MPS IVA)

Mucopolysaccharidosis VI (MPS VI)

Tay-Sachs Disease

Chronic Deficiency of Adenosine Deaminase

Phenylketonuria / Hyperphenylalaninemia
Other Enzyme Replacement Therapies
Exocrine Pancreatic Insufficiency: Porcine-Derived ERT
Exocrine Pancreatic Insufficiency: Recombinant ERT
Others

I would like to order

Product name: Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

Product link: <https://marketpublishers.com/r/C189DEB1582EN.html>

Price: US\$ 2,100.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C189DEB1582EN.html>